Table 1 Clinicopathological characteristics of the endometrial cancer patients included in the study.

Patient	Histology	Grade	FIGO	Myometrial infiltration	Lymph node invasion	POLE status	MSI status	TP53 IHC^a	TCGA classification	Metastasis	Status^b	RFS (years)	OS (years)
EEC-3	Endometrioid	2	IB	80%	No	WT	Negative	1+	CN-low	Iliac node	AWD	3.1	10.9
EEC-4	Endometrioid	2	IA	40%	No	WT	Positive-low	1+	CN-low	Peritoneum	DF	3.12	10.18
EEC-5	Endometrioid	3	IV	100%	Yes	WT	Positive-high	2+	MSI	Peritoneum	DOC	0.26	10.37
EEC-6	Endometrioid	3	IB	75%	No	WT	Positive-high	1+	MSI	Ovary	DOD	1.21	6.73
EEC-7	Endometrioid	3	IB	<50%	No	WT	Positive-high	1+	MSI	Diaphragm	AW	7.81	12.73
SEC-1	Serous	3	IIIB	95%	–	WT	Negative	0	Serous-like	Ovary	DOD	0.21	1.57
SEC-2	Serous	3	IIIA	80%	–	WT	Negative	2+	Serous-like	Ovary	AWD	0.49	1.51
SEC-3	Serous	3	IIIA	<50%	No	WT	Negative	2+	Serous-like	Ovary	DOD	1.4	2.32
AEC	Ambiguous	3	IIIC	95%	Yes (11/36)	WT	Negative	1+	Serous-like	Node	DOD	0.97	2.25

PDX patient-derived xenograft, WES whole-exome sequencing, CNA copy number aberration, P primary tumor, M metastasis.
^aTP53 IHC: 2+ = p53 overexpression, indication of missense mutation; 1+ = wild-type pattern; 0 = absence of protein, indication of null mutation.
^bAW alive and well, AWD alive with disease, DF disease free, DOC died of other cause, DOD died of disease.
All patients received the conventional treatment caboplatin-Taxol.

Quick links

Search